Navigation Links
Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
Date:1/20/2009

n be completed with our current balance sheet, will provide Nile with the opportunity to continue strategic discussions while building value from a meaningful clinical study."

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. Current therapies for acute heart failure, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing renal function. The Company believes that these biochemical features, together with preclinical and preliminary clinical data in patients with heart failure, suggest that CD-NP may have a favorable safety and efficacy profile relative to current therapies for acute heart failure. In addition to an initial indication for acute heart failure, CD-NP has potential utility in other indications which include preservation of cardiac function subsequent to acute myocardial infarction, and prevention of renal damage subsequent to cardiac surgery.

About 2NTX-99

2NTX-99 is a small molecule anti-platelet, anti-atherothrombotic agent with nitric oxide donating properties. Mechanistically, 2NTX-99 is believed to inhibit the synthesis and action of thromboxane and enhance prostacyclin production. Prostacyclin and NO work together to inhibit platelet adhesion and aggregation, induce vasodilation and protect the vascular wall from atherogenic stimuli. The unique activity profile of 2NTX-99 suggests potential utility in a range of atherosclerotic, thrombotic, and microvascular diseases, including intermittent claudication, diabetic nephropathy and pulmonary arterial hypertension.

About
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
3. Dr Stephan Rietiker Joins BioCeramic Therapeutics
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
6. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
7. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
8. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
9. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
10. Horizon Therapeutics Announces Senior Management Appointments
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...e their cell phones and other personal electronics...e by UC San Diego engineers could lead to carbon n...his. , In recent research, published in Applie... in the UCSD Department of Mechanical and Aerospac...efer, have found that artificially introduced defe...
(Date:11/19/2009)...Call/ -- NeoStem, Inc. (NYSE Amex: NBS ), announc...its shareholders, discussing the Company,s acquisi...cals Holdings, Inc. (CHBP), an integrated bio-phar...of China. The merger gives NeoStem a controlling 5..., CHBP,s primary operating subsidiary and a promin...
(Date:11/19/2009)...nd recognized refractive and cataract surgery expe...their fellow surgeons up-to-date on the latest dev...urgery, and ophthalmology in general at the recent...O) annual meeting in San Francisco, California. Dr... Huang, MD, Dr. Randy Epstein, Dr. William Trattle...
(Date:11/18/2009)...ards and Technology (NIST) has demonstrated a rela...d measuring elusive hazards such as concealed expl...esticides distributed in soil by wind and rain. Th...onal techniques for detecting traces of these mate... distinct electrically positive and negative endsa...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9Prototype NIST method detects and measures elusive hazards 2
.... 14 EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-s...s for the treatment of cancer and inflammatory dis...nt and Chief Executive Officer,will present a Corp...nual,Growth Conference, to be held at the St. Regi...-20, 2007. Mr. Burns, presentation is scheduled fo...
...s 90-day review period-, SOUTH SAN FRANCISCO, Cal...ay announced that the company has,submitted a comp...ithKline,(GSK). As announced in August 2007, GSK r...e compound reaches proof-of-concept as defined und...greement between the two,companies. GSK now has 90...
... Calif., Sept. 13 VaxGen,Inc. (Pink Sheets: VXGN)...sistent with its continuing commitment to align it...tiatives. (Logo: http://www.newscom.com/cgi-bin/... workforce from 61 to 27 employees, which the,comp...es used in operating,activities to $1.4 million. T...
Other Biology Technology:EntreMed to Present at ThinkEquity Partners' 5th Annual Growth Conference 2Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives 2
(Date:11/20/2009)... , In the current online issue of the Journa... and Dr. Kilian Eyerich together with their collea...mopatico dell,Immacolata in Rome, present their gr...on the way to developing new treatment methods for...allergic reactions and potentially also allergic r...
(Date:11/20/2009)...hers report that a class of heart medications call...ffect on the heart, depending on their molecular a...al Circulation Research , found that beta-blocker...n the heart muscle offer the most benefit to cardi...-receptors can actually undermine the structure an...
(Date:11/19/2009)...ling the genetic instructions inside corn, one of ...e of the most complex sequences of DNA ever analyz...t David Schwartz, who was one of more than 100 aut..."The maize genome is a true maze full of confusin...e sequencers for years," says Schwartz. , Public...
Breaking Biology News(10 mins):Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3State Launches New Campaign to Help Pregnant Smokers Go Tobacco Free 49623 1State Launches New Campaign to Help Pregnant Smokers Go Tobacco Free 49623 2Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery 49620 1Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery 49620 2Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery 49620 3BRAHMS Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 12727 1BRAHMS Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 12727 2BRAHMS Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 12727 3
...ug. 28 Gamma globulin, a type of antibody isolate...en to health care workers and international travel... highly effective treatment for pinkeye with littl...rchers at the University of Pittsburgh School of M... in the September 1 issue of the journal Investiga...
...ncer is one of the most prevalent cancers in the W...then turns into an invasive and violent cancer, wh...ntly published in the journal Cancer Research, Pro...ann Institutes Molecular Cell Biology Department r.... , In a majority of cases, colorectal cancer is ...
...Pennsylvania researchers have designed a nanoscale...s react to external forces. , , By combining mic...hnology to create independent, nanoscale sensors, ...ces and demonstrated a dynamic biological relation...study also revealed that cells sense force at a si...
Other Biology News:Gamma globulin effective in treating eye infections caused by adenoviruses 2A gene for metastasis 2Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces 2
29.5" 18" Dedicated Platform with (61) 125ml Clips, for Stackable Shakers from Thermo Scientific
...ne high durability and performance with class-lead... patented triple-counterbalanced heavy-duty mechan...ith heavy out-of-balance loads. The patented HEPA...vy stainless steel interior has coved corners and ...
Cellject Uno 220V includes instruction manual, optimization guide and 10 cuvettes (5 2 mm and 5 4 mm) from Thermo Scientific
Mouse Anti-Bovine GTP BINDING PROTEIN Monoclonal Antibody, Unconjugated, Clone 1H6 from AbD Serotec
Biology Products: